Protocols: Bavarian collaborates with BMS on lung cancer study; Eleven completes Roche deal; Intellia chief anticipates new CRISPR tweaks
Following up on its big setback for non-small cell lung cancer, Bristol-Myers has agreed to supply its checkpoint drug to Denmark’s Bavarian Nordic, which plans to enroll 165 patients in a Phase II lung cancer study that will get a combination of Opdivo and its antigen-targeting CV301. The study will focus on previously treated patients. Opdivo is already approved in the second-line setting. There has been an explosion of collaborations in immune-oncology over the past two years.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.